AshCure Pharma and 1Point Pharma sign agreement to deliver pharmaceuticals to the Nordics

AshCure is an independent pharmaceutical company primarily engaged in the development, licensing and supply of generic drugs and medical devices to hospitals and pharmacies, giving patients access to high-quality medicines.

As a new market entrant, 1Point Pharma offers plug-and-play access to the Nordic pharmaceutical markets with a proven, simple and cost-effective business model – with management of supply chain, pricing, quality, business development and sales.

Director and CEO of AshCure, Parminder Kaur, says: “As a new player in the pharmaceutical industry, with this agreement we take an important step towards commercialization with the support of 1Point Pharma, a trusted distribution partner with an established presence in Denmark and across the Nordics. Together, our companies can deliver value-added and affordable medicines to patients in need through pharmacy chains and hospitals.”

Managing Director of 1Point Pharma, Morten Carl Madsen, says: “We are excited about the agreement with AshCure, a serious new pharma company with great potential. Our business model is focused on supply continuity and taking responsibility for keeping products on the shelves by monitoring market movements. It is in our DNA to be transparent to our partners and the market with a positive approach to the authorities. We offer a straightforward model with a fixed revenue split so our partners know what they can count on."

AshCure is also supported by its sister company, RegPak BioPharma Consulting, a recognized consulting firm that provides comprehensive support for product registration within the EU.